Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF36) health survey questionnaires. Results: The menstrual blood size was (60.287 +/- 21.832) (41.186 +/- 16.153), (30.988 +/- 15.670), (19.238 +/- 13.649), (16 +/- 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 +/- 33.775,p < 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 +/- 15.889) to (38.797 +/- 16.781), (24.857 +/- 16.595), (15.840 +/- 14.305), (10.784 +/- 13.593), and (8.196 +/- 12.919), respectively, after treatment one, three, six, 12, and after 18 months of the LNG-IUS insertion (p < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.